SUBSCRIBE
SUBSCRIBE

Apnimed

39 John F Kennedy Street Cambridge MA 02138 US
Visit website
Email Us
  • Featured Employer
JOBS
IN THE PRESS
Press Releases
Apnimed Announces Early Completion of Enrollment in Phase 3 SynAIRgy Study of AD109, the First Potential Oral Treatment Addressing the Neuromuscular Cause of Obstructive Sleep Apnea
September 19, 2024
 · 
6 min read
Press Releases
Apnimed to Present New Findings on the Prevalence of Obesity Hypoventilation Syndrome (OHS) at the European Respiratory Society (ERS) Congress 2024
September 4, 2024
 · 
2 min read
Genetown
Apnimed Announces a Robust Slate of Presentations at SLEEP 2024, Including an Analysis of the Prevalence of Obesity in Obstructive Sleep Apnea
May 23, 2024
 · 
8 min read
Drug Development
Apnimed Announces Completion of Enrollment in Phase 3 LunAIRo Study of AD109, the Potential First Nighttime Oral Treatment for Obstructive Sleep Apnea
May 9, 2024
 · 
7 min read
Genetown
Apnimed to Participate in the Upcoming Leerink Partners Global Biopharma Conference
March 6, 2024
 · 
3 min read
Genetown
Apnimed to Participate in the Upcoming Evercore ISI 2024 Emerging Biotech Conference
February 22, 2024
 · 
3 min read
Business
Apnimed Announces New Leadership Appointments as the Company Builds Its Commercial and Human Resource Capabilities in Support of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea
January 22, 2024
 · 
6 min read
Drug Development
Apnimed Announces First Patient Dosed in SynAIRgy, the Second Phase 3 Clinical Study of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea
December 21, 2023
 · 
5 min read
Genetown
Apnimed to Participate in Upcoming November 2023 Investor Conferences
November 6, 2023
 · 
3 min read
Genetown
Apnimed Announces Launch of Joint Venture with Shionogi to Develop Novel Pharmacologic Therapies for Obstructive Sleep Apnea and other Sleep Disorders
October 31, 2023
 · 
5 min read
Load More